诺和诺德称CagriSema击败了礼来公司的Zepbound

2026-09-21 22:30

Novo Nordisk (NVO) said that results from a phase 3 trial found that its experimental, once-weekly obesity treatment CagriSema (cagrilintide and semaglutide) achieved better weight loss results compared to a 5 mg dose of rival Eli Lilly's (LLY) weekly injection Zepbound (tirzepatide).
Data from REIMAGINE 5 found CagriSema 1 mg/1 mg led to an estimated average weight loss of 12.4% vs. 9.1% on Zepbound at week 60. CagriSema also showed non-inferior reduction in HbA1c compared to Zepbound.
Patients enrolled in this trial had type 2 diabetes.
In REDEFINE 9, which enrolled overweight and obese patients, those on CagriSema had weight loss of 21% vs. 2% for placebo. Zepbound was not included in this study.
The Zepbound dose tested is one of the lower doses available, as it comes in doses ranging from 2.5 mg to 15 mg. Tirzepatide is also sold by Lilly as a type 2 diabetes medication under Mounjaro with the same dosage range.

More on Novo Nordisk